Genasense
hillby
Member Posts: 31
Hi all:
This is a small exerpt from San Diego's Ranch and Coast Mag (July 2006). Has anyone ever heard of this? It is up for fast track FDA approval this summer. Anyone who knows about this, I would love your input....
Every day, over 50 billion cells commit suicide within us. Reed's pioneering research has unraveled the mysteries of both how and why some cells die on schedule and others refuse to die. Those cells that act immortal lead to cancer and other chronic diseases. He came up with an idea in the mid-1990s to develop synthetic DNA to shut off the immortal function of cancerous cells. This technology was purchased by a pharmaceutical company, Genta, formerly based in San Diego (now in New Jersey). Genta then developed the drug Genasense, the first DNA-based cancer drug to pass phase III FDA clinical trials.
Genasense will be up for approval by the FDA and the European Union this summer. If it passes, it has the potential to treat millions afflicted with cancer. From his office at the Burnham campus on the Torrey Pines mesa, Reed optimistically talks about the healing potential of Genasense. It's a late, rainy Friday afternoon. Reed has been just informed by his wife, Muffy - a philanthropist who has chaired Burnham's yearly fundraising gala for the last five years - that one of their three sons, Tyler, 15, has just broken his collarbone playing lacrosse. (Reed's two other sons are Hunter, 17, and Courtland, 12.)
"I'm really excited about the potential of Genasense," says Reed, staying positive despite the bad news. "It's an innovative drug that will convince the cells to die as opposed to murdering the cells through radiation."
It's rare that scientists invent a drug that gets to market. Reed's creation will target a gene that is responsible for causing half of all cancers.
"Genasense has been empirically effective on myeloma and other cancers, such as melanoma, leukemia, lymphoma, and cancers of the lung and colon," says Reed, who also mentions the drug's efficacy on prostate cancer.
This is a small exerpt from San Diego's Ranch and Coast Mag (July 2006). Has anyone ever heard of this? It is up for fast track FDA approval this summer. Anyone who knows about this, I would love your input....
Every day, over 50 billion cells commit suicide within us. Reed's pioneering research has unraveled the mysteries of both how and why some cells die on schedule and others refuse to die. Those cells that act immortal lead to cancer and other chronic diseases. He came up with an idea in the mid-1990s to develop synthetic DNA to shut off the immortal function of cancerous cells. This technology was purchased by a pharmaceutical company, Genta, formerly based in San Diego (now in New Jersey). Genta then developed the drug Genasense, the first DNA-based cancer drug to pass phase III FDA clinical trials.
Genasense will be up for approval by the FDA and the European Union this summer. If it passes, it has the potential to treat millions afflicted with cancer. From his office at the Burnham campus on the Torrey Pines mesa, Reed optimistically talks about the healing potential of Genasense. It's a late, rainy Friday afternoon. Reed has been just informed by his wife, Muffy - a philanthropist who has chaired Burnham's yearly fundraising gala for the last five years - that one of their three sons, Tyler, 15, has just broken his collarbone playing lacrosse. (Reed's two other sons are Hunter, 17, and Courtland, 12.)
"I'm really excited about the potential of Genasense," says Reed, staying positive despite the bad news. "It's an innovative drug that will convince the cells to die as opposed to murdering the cells through radiation."
It's rare that scientists invent a drug that gets to market. Reed's creation will target a gene that is responsible for causing half of all cancers.
"Genasense has been empirically effective on myeloma and other cancers, such as melanoma, leukemia, lymphoma, and cancers of the lung and colon," says Reed, who also mentions the drug's efficacy on prostate cancer.
0
Comments
-
Genasense is an "antisense" compound. This class of compounds have been studied for several years in several diseases including cancer. The science of antisense technology is very exciting and has great promise because of how it works in the lab. However, in general antisense drugs have not yet lived up to expectations in clinical trials except in a few isolated areas. This one, Genasense, blocks a protein (Bcl-2)involved in blocking chemotherapy induced cell death. The thinking is that if you block Bcl-2, then standard chemotherapy drugs will work better at killing cancer cells.
Unfortunately there are news reports today about Genasense(check out NY Times online)which are less than favorable.
Howard0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.9K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 398 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 793 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 63 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 540 Sarcoma
- 732 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards